Literature DB >> 10767720

Inactive matrix metalloproteinase 2 is a normal constituent of human glomerular basement membrane. An immuno-electron microscopic study.

S M Jalalah1, P N Furness, G Barker, M Thomas, L L Hall, G R Bicknell, J A Shaw, J H Pringle.   

Abstract

Remodelling of the extracellular matrix requires tight control not only of matrix synthesis, but also of matrix degradation. Control of matrix degradation is achieved mainly through the matrix metalloproteinase (MMP) enzymes. In the glomerulus, MMP-2 and MMP-9 are believed to be particularly important, as they have activity against type IV collagen. This study has demonstrated by immuno-electron microscopy that most of the immunoreactivity for MMP-2 in the normal glomerulus is located within the glomerular basement membranes and mesangial matrix. mRNA for MMP-2 is also detectable in normal glomeruli, but the other main gelatinase, MMP-9, could not be localized by immuno-electron microscopy. In the normal glomerulus, it seemed likely that MMP-2 is present in an inactive form. To confirm this, in situ zymography was carried out using frozen sections of normal kidney. Baseline activity of normal kidney was relatively weak, but this was dramatically increased by chemical activation of metalloproteinases. The results imply that MMP-2, in an inactive form, is a normal constituent of the extracellular matrix and glomerular basement membranes. Activation would presumably render the matrix 'self-degrading'; membrane-bound MMPs (MT-MMPs) seem particularly likely to be involved in leukocyte penetration of basement membranes in inflammation. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767720     DOI: 10.1002/(SICI)1096-9896(200005)191:1<61::AID-PATH565>3.0.CO;2-6

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  3 in total

1.  Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy.

Authors:  Makiho Sekiuchi; Akihiko Kudo; Kimimasa Nakabayashi; Masami Kanai-Azuma; Yoshihiro Akimoto; Hayato Kawakami; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2012-05-22       Impact factor: 2.801

2.  Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining.

Authors:  Tetsuya Endo; Kimimasa Nakabayashi; Makiho Sekiuchi; Tadahide Kuroda; Akinori Soejima; Akira Yamada
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

3.  Renoprotective action of a matrix metalloproteinase inhibitor in progressive mesangioproliferative nephritis.

Authors:  Takayuki Kuroda; Masao Masui; Mitsuru Notoya; Masashi Ito; Yoshinori Tamura; Hiroyuki Okamoto; Eri Kanaoka; Toshihiro Shinosaki
Journal:  Nephron Extra       Date:  2012-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.